Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | CCNB2 | O95067 | 8/20 | 0.34 |
| ▸ | CDK1 | P06493 | 8/20 | 0.34 |
| ▸ | CCNB1 | P14635 | 8/20 | 0.34 |
| ▸ | GSK3B | P49841 | 8/20 | 0.34 |
| ▸ | CCNB3 | Q8WWL7 | 8/20 | 0.34 |
| ▸ | GSK3A | P49840 | 7/20 | 0.34 |
| ▸ | CDK5 | Q00535 | 7/20 | 0.34 |
| ▸ | CDK5R1 | Q15078 | 7/20 | 0.34 |
| ▸ | GRM4 | Q14833 | 4/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.32 |
| ▸ | CDK2 | P24941 | 2/20 | 0.32 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.32 |
| ▸ | INSR | P06213 | 1/20 | 0.32 |
| ▸ | CFTR | P13569 | 1/20 | 0.32 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.32 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18357966 | 0.76 | PDK2 (0.36) | PDPK1MAPK1CCNB2CDK1CCNB1 | |
| SCHEMBL6358084 | 0.75 | MAPK1 (0.38) | MAPK1GRM4YTHDC1YTHDF2 | |
| SCHEMBL19258970 | 0.73 | YTHDC1 (0.40) | PDPK1MAPK1GRM4YTHDC1YTHDF2 | |
| SCHEMBL17455475 | 0.73 | PDPK1 (0.53) | PDPK1CYP1A2DYRK1A | |
| SCHEMBL3954043 | 0.73 | MAPK1 (0.44) | PDPK1MAPK1CDK5DYRK1A | |
| SCHEMBL20247408 | 0.73 | MAPK1 (0.33) | PDPK1MAPK1 | |
| SCHEMBL30876173 | 0.71 | MAPK1 (0.35) | MAPK1CCNB2CDK1CCNB1GSK3B | |
| SCHEMBL30316980 | 0.71 | MAPK1 (0.35) | MAPK1GRM4 | |
| SCHEMBL14906033 | 0.71 | MAPK1 (0.45) | MAPK1 | |
| SCHEMBL30180924 | 0.71 | DYRK1A (0.38) | PDPK1MAPK1CCNB2CDK1CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2007504243-A | — | — | 2007-03-01 | — | — | JP | claimed |
| EP-1675858-A2 | 5-ARYL-PYRAZOLO [4,3-D] PYRIMIDINES, PYRIDINES, AND PYRAZINES AND RELATED COMPOUNDS | NEUROGEN CORPORATION (US) | 2006-07-05 | — | — | EP | claimed |
| WO-2005028480-A2 | 5-ARYL-PYRAZOLO[4,3-D]PYRIMIDINES, PYRIDINES, AND PYRAZINES AND RELATED COMPOUNDS | NEUROGEN CORPORATION (US) | 2005-03-31 | — | — | WO | claimed |
| EP-4219465-A2 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme Inc (US) | 2023-08-02 | — | — | EP | disclosed |
| US-20230102554-A1 | HETEROCYCLIC KINASE INHIBITORS AND PRODUCTS AND USES THEREOF | GB002, INC. | 2023-03-30 | — | — | US | disclosed |
| EP-3498701-B1 | PRMT5 INHIBITORS AND USES THEREOF | EPIZYME INC (US) | 2023-02-22 | — | — | EP | disclosed |
| EP-3990443-A1 | HETEROCYCLIC KINASE INHIBITORS AND PRODUCTS AND USES THEREOF | GB002, Inc. (US) | 2022-05-04 | — | — | EP | disclosed |
| WO-2021126995-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | ENGINE BIOSCIENCES PTE. LTD. (SG) | 2021-06-24 | — | — | WO | disclosed |
| WO-2020264420-A1 | HETEROCYCLIC KINASE INHIBITORS AND PRODUCTS AND USES THEREOF | GB002, INC. (US) | 2020-12-30 | — | — | WO | disclosed |
| WO-2020264420-A1 | HETEROCYCLIC KINASE INHIBITORS AND PRODUCTS AND USES THEREOF | GB002, INC. (US) | 2020-12-30 | — | — | WO | disclosed |
| EP-2935247-B1 | PRMT5 INHIBITORS AND USES THEREOF | EPIZYME INC (US) | 2019-08-28 | — | — | EP | disclosed |
| US-20140221336-A1 | COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-07 | — | — | US | disclosed |
| US-20120157429-A1 | COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2012-06-21 | — | — | US | disclosed |
| US-20120157429-A1 | COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2012-06-21 | — | — | US | disclosed |
| US-20100168097-A1 | Non-Nucleoside Reverse Transcriptase Inhibitors | MERCK SHARP & DOHME CORP. | 2010-07-01 | — | — | US | disclosed |
| US-20100160287-A1 | COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-24 | — | — | US | disclosed |
| US-20100160287-A1 | COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-24 | — | — | US | disclosed |
| WO-2009032653-A1 | INHIBITORS OF AKT ACTIVITY | SMITH KLINE BEECHAM CORPORATION (US) | 2009-03-12 | — | — | WO | disclosed |
| WO-2009032653-A1 | INHIBITORS OF AKT ACTIVITY | SMITH KLINE BEECHAM CORPORATION (US) | 2009-03-12 | — | — | WO | disclosed |
| WO-2008116139-A2 | N-HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157429-A1 | COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES | JAK2, JAK1, JAK3 | PDPK1 102/4885MAPK1 215/4885CCNB2 1848/4885 |
| US-20100168097-A1 | Non-Nucleoside Reverse Transcriptase Inhibitors | RNGTT, POLR1E, RTF1 | PDPK1 3198/4885MAPK1 2083/4885CCNB2 458/4885 |
| US-20100160287-A1 | COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES | JAK2, JAK1, JAK3 | PDPK1 102/4885MAPK1 215/4885CCNB2 1848/4885 |
| US-20230102554-A1 | HETEROCYCLIC KINASE INHIBITORS AND PRODUCTS AND USES THEREOF | PDGFRB, PDGFRA, FGFR1 | PDPK1 487/4885MAPK1 232/4885CCNB2 837/4885 |
| US-20140221336-A1 | COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES | JAK2, JAK1, JAK3 | PDPK1 102/4885MAPK1 215/4885CCNB2 1848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.